Show Notes
In this episode, tech transfer expert and lecturer Joe Brady explains why most projects are “already late on day one” and unpacks the real causes of delay across the product lifecycle, from stability studies and PPQ batches to warehouses, materials, and analytical methods. He contrasts innovator to innovator with innovator to CMO transfers, shares hard‑won lessons on auditing, scaling legacy products, and soft‑skill pitfalls with CMOs, and explores how knowledge management, digitisation, and AI will reshape how pharma approaches tech transfer.
Contact us at: [email protected]
This episode is sponsored by STERIS.
More from Pharma Conversations Podcast
In this episode, Brendan McGrath shares his story of him being the first employee of WuXi Biologics in Ireland and how he helped turn an empty site into a 46,000 m² biologics facility in Dundalk. He shares the greenfield risk he took, building through COVID and Brexit with 1,800 workers on site, and where automation, predictive data and sustainability are taking pharma manufacturing next.
Executive Director of the ARC Hub* for Therapeutics, Araz Raoof, joins Pharma Conversations to unpack why Europe leads the world in scientific papers yet lags in new drug approvals, and how Ireland’s ARC Hub for Therapeutics is trying to change that.
In this episode of Pharma Conversations, Paul McCabe, COO of APC/VLE unpacks the hidden world of Ireland’s indigenous biopharma SMEs, and why, despite a world-class multinational presence, the ecosystem is incomplete.
Sustainability in pharma isn’t a side project anymore – it’s fast becoming core operational excellence. In this episode of Pharma Conversations, we sit down with Michael Kilkelly (IBEC) to explore how Irish pharma is leading on decarbonisation, the real challenges behind scope 1–3 emissions, and practical ways to embed sustainability from the boardroom to the cleanroom. A must-listen for anyone serious about turning ESG into measurable results.
In this episode John Shabushnig, founder of Insight Pharma Consulting explains what visual inspection really means for injectable products, from manual methods to advanced automated systems. He tackles difficult-to-inspect products, visible particle risk, and common pitfalls in validating automation. John also shows how life-cycle thinking turns inspection data into real process and quality improvements.